# Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

> **NCT03269695** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 20 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** PF-06687234
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03269695
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-20
- **Primary completion:** 2021-01-07
- **Final completion:** 2021-01-07
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The Sponsor changed R\&D strategy and priority.
- **Last updated:** 2021-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03269695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03269695, "Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03269695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*